Sign In
Buy PODD
$143.90
+4.93 (+3.55%)
At Close: Jun 23, 2026
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
10:45am, Tuesday, 23'rd Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
09:47am, Tuesday, 23'rd Jun 2026
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
Insulet Corporation (PODD) Discusses Recent Product Recalls and Physician Community Response at ADA Meeting Transcript
07:12pm, Friday, 12'th Jun 2026
Insulet Corporation (PODD) Discusses Recent Product Recalls and Physician Community Response at ADA Meeting Transcript
Why Insulet (PODD) is a Top Momentum Stock for the Long-Term
10:52am, Thursday, 11'th Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Insulet Corporation Valuation Pressure Has Dropped Enough (Upgrade)
02:40pm, Monday, 08'th Jun 2026
Insulet Corporation has rebounded with strong revenue and profit growth, now approaching the lower end of fair value. PODD delivered Q1 2026 revenue of $761.7M (+33.9% YoY), with net income and operat
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in [url="]tubeless insulin pump[/url] technology with its Omnipod brand of pro
Why Is Insulet (PODD) Down 8.7% Since Last Earnings Report?
12:35pm, Friday, 05'th Jun 2026
Insulet (PODD) reported earnings 30 days ago. What's next for the stock?
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?
11:50am, Thursday, 04'th Jun 2026
DexCom posts steady profits and global reach, while Insulet surges ahead with rapid revenue growth and a focused product line. Which strategy stands out?
ACTON, Mass.--(BUSINESS WIRE)--Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at ADA.
Insulet Corporation (PODD) Presents at 46th Annual William Blair Growth Stock Conference Transcript
05:22pm, Wednesday, 03'rd Jun 2026
Insulet Corporation (PODD) Presents at 46th Annual William Blair Growth Stock Conference Transcript
Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor
08:00am, Wednesday, 03'rd Jun 2026
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in [url="]tubeless insulin pump technology[/url] with its Omnipod brand of pro
Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor
07:00am, Wednesday, 03'rd Jun 2026
ACTON, Mass.--(BUSINESS WIRE)--Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor.
Insulet (PODD) is a Top-Ranked Growth Stock: Should You Buy?
10:46am, Tuesday, 02'nd Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
PODD Stock: What a Hold Rating Says at a $163 Target
10:56am, Thursday, 28'th May 2026
Insulet earns a short-term Hold as outlook rises; a $163 sales-based target tests whether growth can beat 2026 volatility.
US court overturns Insulet's $452 mln insulin-pump trade secret verdict against EOFlow
10:34am, Thursday, 28'th May 2026
A U.S. appeals court on Thursday overturned a $452 million verdict that medical device maker Insulet won against Korean rival EOFlow for allegedly stealing trade secrets related to i
